LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

FibroGen Inc

Closed

SectorHealthcare

8.47 -1.51

Overview

Share price change

24h

Current

Min

8.31

Max

8.69

Key metrics

By Trading Economics

Income

208M

201M

Sales

-272K

1.1M

EPS

49.61

Profit margin

18,646.468

Employees

225

EBITDA

6.1M

-5.4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+394.82% upside

Market Stats

By TradingEconomics

Market Cap

-40K

44M

Previous open

9.98

Previous close

8.47

News Sentiment

By Acuity

23%

77%

51 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

FibroGen Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 lut 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 lut 2025, 11:30 UTC

Acquisitions, Mergers, Takeovers

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

Peer Comparison

Price change

FibroGen Inc Forecast

Price Target

By TipRanks

394.82% upside

12 Months Forecast

Average 43 USD  394.82%

High 43 USD

Low 43 USD

Based on 2 Wall Street analysts offering 12 month price targets forFibroGen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

0.306 / 0.33939Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

51 / 374 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

help-icon Live chat